8-K: FOXO Technologies Announces 2024 Annual General Meeting Details

FOXO Technologies Inc. will hold its 2024 Annual General Meeting virtually on December 31, 2024, to approve directors and auditors.

Summary

• FOXO Technologies Inc. has announced its 2024 Annual General Meeting of Shareholders will be held virtually on December 31, 2024, at 9:30 am CST.
• Shareholders of record on December 19, 2024, are eligible to vote on the proposals.
• The meeting will be conducted via live webcast, and shareholders can register online to attend, vote, and submit questions.
• The company is seeking shareholder approval for directors and auditors at the meeting.
• FOXO also plans to hold a Special Meeting soon for other matters requiring shareholder approval.
• According to the CEO, 2024 has been a transformative year for FOXO, with all NYSE American listing deficiencies fixed and significant revenue-generating businesses acquired.
• The company believes its acquisition and growth strategy will drive significant growth and value in 2025 and beyond.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's claims of fixing listing deficiencies and acquiring revenue-generating businesses, but it is tempered by the inherent risks and uncertainties associated with forward-looking statements.

Positives

• The company has successfully addressed all deficiencies required for continued listing on the NYSE American.
• FOXO has acquired significant revenue-generating businesses, indicating a positive shift in its financial position.
• Management believes the company's acquisition and growth strategy will lead to substantial growth and value creation in 2025 and beyond.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• There is a risk that the company may not be able to satisfy all continued listing requirements of NYSE American.
• The company operates in highly competitive and regulated industries, which could impact its performance.
• There is a risk that the company may not achieve or maintain profitability in the future.
• The company's ability to implement its business plans and obtain financing is subject to risk.
• The company's intellectual property may be subject to infringement, and the company may not be able to enforce its patents.
• Downturns and changes in the regulatory landscape in the biotechnology and insurance industries could negatively impact the company.

Future Outlook

FOXO anticipates significant growth and value creation in 2025 and beyond, driven by its acquisition and growth strategy.

Management Comments

• We look forward to ending the year with our 2024 Annual General Meeting to have our shareholders approve our directors and auditors, said Seamus Lagan, CEO of FOXO.
• 2024 has been a transformative year for FOXO.
• We are ending the year with all deficiencies for our NYSE American continued listing requirements fixed, significant revenue generating businesses acquired and an acquisition and growth strategy that we believe will propel significant growth and value in 2025 and beyond.

Industry Context

The announcement of the Annual General Meeting is a routine corporate event, but the comments about fixing listing deficiencies and acquiring revenue-generating businesses suggest a strategic shift for FOXO in the competitive biotechnology and healthcare sectors.

Comparison to Industry Standards

• Many biotechnology and healthcare companies hold annual general meetings to engage with shareholders and seek approval on key matters.
• The focus on acquisitions and growth strategy is common among companies looking to expand their market presence and revenue streams.
• The mention of fixing NYSE American listing deficiencies suggests that the company has been under scrutiny and is now taking steps to improve its compliance and standing.

Stakeholder Impact

• Shareholders will have the opportunity to vote on key proposals and engage with management at the Annual General Meeting.
• Employees may be impacted by the company's growth and acquisition strategy.
• Customers of FOXO's subsidiaries may see changes in services and products as the company grows.
• Suppliers and creditors may be impacted by the company's financial performance and growth.

Next Steps

• Shareholders will attend the virtual Annual General Meeting on December 31, 2024.
• Shareholders will vote on the proposals listed on the Proxy Card.
• The company will hold a Special Meeting as soon as practical for other matters needing shareholder approval.

Key Dates

Keywords

Annual General Meeting, Shareholders, NYSE American, Listing Requirements, Acquisition, Growth Strategy, Virtual Meeting, Biotechnology, Healthcare, Revenue